Levation Pharma

Levation Pharma is an Israeli-American company that is relating to the treatment of Acquired Blepharoptosis. Acquired Blepharoptosis is a condition in which the upper eyelids droop. Though this condition is occasionally seen in association with serious diseases, the majority of patients develop the condition as part of the natural aging process. Some patients with this condition may complain of reduced vision. The company developed LEV-102, a proprietary odorless, colorless, rapidly drying aqueous gel. It is intended to be applied in small volume to the upper lids, similar to eyeshadow. For patients who also use eyeshadow for cosmetic purposes, LEV-102 is designed to function as an eyeshadow primer. The active pharmaceutical ingredient in LEV-102 is a drug called oxymetazoline. The gel also has stabilizers and permeation enhancers. LEV-102 is designed so that the oxymetazoline can penetrate the upper lid and reach the tiny involuntary ‘fight or flight’ muscle in the lid called Mueller’s muscle. The drug then binds to the muscle and triggers a slight contraction that is designed to lift the upper lid in a similar manner to what one might see if a person is suddenly startled.

Levation Pharma has raised $1.93M in total funding across 1 rounds. The company is currently at the Seed stage. Key investors include Peregrine Ventures, Pontifax.

Levation Pharma was founded in 2017 by Houman David Hemmati MD, PhD (Co-Founder & Chief Scientific Officer ).

Levation Pharma operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Cosmetics.

Levation Pharma is based in Rothschild Boulevard 45, Tel Aviv-Yafo, Israel, Center District.